Farmalisa - Spinraza is a medicine used to treat 5q spinal muscular atrophy (SMA), a genetic disease that causes weakness and wasting of the muscles including the lung muscles. The disease is
EMA opinion on broad-label approval for Spinraza – TreatSMA
U.S. FDA Approves Biogen's SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy | Biogen
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study - The Lancet
A potential side effect added to Spinraza label – TreatSMA
Biogen announces new data providing further evidence for SPINRAZA (nusinersen) as a treatment for SMA - Spinal News International
Spinraza (PF) intrathecal: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
Safety | SPINRAZA® (nusinersen) HCP
Spinraza - FDA prescribing information, side effects and uses
What is Spinraza? Uses, Side Effects & More | TheSocialMedwork
Spinraza - NPS MedicineWise
Study design | SPINRAZA® (nusinersen) HCP
Novartis' £1.79M gene therapy Zolgensma scores cost watchdog's backing, threatening Biogen's Spinraza | FiercePharma
Drug Puts A $750,000 'Price Tag On Life' | Kaiser Health News
Roche's low-price Evrysdi will take 'meaningful' SMA share from Biogen's Spinraza: analyst | FiercePharma
HSE approves Spinraza after lengthy campaign by patients
Buy Spinraza (Nusinersen) Online • Price & Costs | TheSocialMedwork
Official HCP Homepage | SPINRAZA® (nusinersen) | HCP
Biogen's blockbuster rare disease drug could be in trouble
Spinraza in the UK ‒ questions and answers – TreatSMA
Spinraza®: coverage for all SMA type 1,2,3 patients - Institut de Myologie
Biogen bounces back with Spinraza early treatment data - PMLiVE
